Fiche centre
John Hunter Hospital
New Lambton Heights — Australia
Essais liés9clinical trials
VilleNew Lambton Heightslocalisation
PaysAustralialocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07282574
Essais cliniques associés
9| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| FARAPULSE™ Pulsed Field Ablation System | Maladie coronarienne | Non applicable | NCT06735534 | ReMATCH — Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System | ACTIVE_NOT_RECRUITING |
| Dapagliflozin 10 mg/day (oral) | Maladie rénale chronique | Phase 3 | NCT05374291 | The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | ACTIVE_NOT_RECRUITING |
| BB-031 | Accident vasculaire cérébral | Phase 2 | NCT06226805 | Study of BB-031 in Acute Ischemic Stroke Patients (RAISE) | RECRUITING |
| Tenecteplase | Accident vasculaire cérébral | Phase 3 | NCT07361302 | TENACITY — A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well | RECRUITING |
| WiSE System | Insuffisance cardiaque | Non applicable | NCT02922036 | SOLVE-CRT — Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients | ACTIVE_NOT_RECRUITING |
| RO7268489 | SEP | Phase 2 | NCT07282574 | Mintaka — A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) | RECRUITING |
| Vicadrostat | Hypertension | Phase 3 | NCT07064473 | EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | RECRUITING |
| CNM-Au8 | SEP | Phase 2/3 | NCT04626921 | VISIONMS-LTE — A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis | COMPLETED |
| CNM-Au8 | SEP | Phase 2 | NCT03536559 | VISIONARY-MS — Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis | TERMINATED |